drugset / Trial / NCT01009840
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
NaSingle-groupOpen-labelTreatment
Summary
Study for the outcome and safety of individualized busulfan dosing with bortezomib for patients preparing for a second stem cell transplant to treat multiple myeloma.
Timeline
- Start
- 2010-05-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Busulfan | Small molecule | — | Intravenous |